전립선비대증을 동반한 발기부전 환자에서 Mirodenafil 50mg 매일 복용요법과 100mg 필요 시 복용요법의 유효성 비교: 다기관, 무작위 대조 연구Comparison of Erectile Dysfunction Treatment Efficacy of Mirodenalfil 50mg Once Daily and 100mg On-Demand in Patients with Benign Prostatic Hyperplasia and Erectile Dysfunction: Multicenter, Randomized
- Other Titles
- Comparison of Erectile Dysfunction Treatment Efficacy of Mirodenalfil 50mg Once Daily and 100mg On-Demand in Patients with Benign Prostatic Hyperplasia and Erectile Dysfunction: Multicenter, Randomized
- Authors
- 조중훈; 서준상; 김규식; 김태효; 노준화; 배재현; 오철영; 이승환; 조성용; 최재덕; 한준현; 이승욱
- Issue Date
- Dec-2015
- Publisher
- 대한비뇨기종양학회
- Keywords
- Mirodenafil; Lower urinary tract symptoms; Erectile dysfunction; Benign prostatic hyperplasia
- Citation
- 대한비뇨기종양학술지, v.13, no.3, pp.115 - 121
- Indexed
- KCI
OTHER
- Journal Title
- 대한비뇨기종양학술지
- Volume
- 13
- Number
- 3
- Start Page
- 115
- End Page
- 121
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/155610
- ISSN
- 1598-8341
- Abstract
- Purpose: To Compare the improvement of erectile dysfunction(ED) and lower urinary tract symptoms(LUTS) as well as the efficacy of mirodenalfil 50mg once daily and 100mg on-demand in patients with benign prostatic hyperplasia(BPH) and erectile dysfunction(ED). Materials and Methods: Prospective study was done with 220 patients who had BPH and ED from June 2013 to October 2014. Out of 220 individuals, 260 met inclusion criteria and 204 finished the research. Patients were divided into two groups. Group 1 had mirodenafil 50mg once daily and Group 2 had mirodenafil 100mg on-demand. The five-item version of the International Index of Erectile Function(IIEF-5), International Prostate Symptom Score(IPSS), Qmax, and residual urine volume(PVR) were assessed immediately before initiation of treatment(V1) and after four(V2) and twelve weeks of treatment(V3). Results: No difference of IIEF-5, IPSS, Qmax, and PVR between two groups in V1. At V3, both groups had improvements of IPSS and group 1 had better improvements(-5.1±4.4 vs. -3.1±3.9 p<0.001). And Group 1 had larger improvements than Group 2 in Qmax significantly. No difference in PVR in both groups comparing V1 vs. V2 and V1 vs V3. Group 1 had better improved IIEF-5 than Group 2(V1 vs. V3 : 4.8±5.8 vs. 4.4±5.1; p=0.032). There was no drop out patients due to cardiovascular problems. Conclusions: Once daily mirodenafil 50mg was more efficacious in treating both ED and LUTS than on-demand dosing mirodenafil 100mg without any complication of cardiovascular problems.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 의과대학 > 서울 비뇨의학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/155610)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.